GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Amneal Pharmaceuticals AMRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

21.28

+5.66%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$3.02bn

FY2016FY2025

Net income

$72.1m

FY2016FY2025

Free cash flow

$269.9m

FY2016FY2025

Shareholders' equity

−$70.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$3.02bn$2.79bn$2.39bn$2.21bn$2.09bn$1.99bn$1.63bn$1.66bn$1.03bn$1.02bn
Research and development$186.2m$190.7m$194.8m$208.7m$209.6m$190.6m$202.3m$210.5m$191.9m$204.7m
Operating income$423.1m$249.3m$204.4m−$94.9m$167.7m$91.2m−$248.7m−$157.1m$245.1m$284.9m
Net income$72.1m−$116.9m−$84.0m−$130.0m$10.6m$91.1m−$361.9m−$169.7m$167.6m$207.4m
Diluted earnings per share0.22-0.38-0.34-0.860.070.62-2.55-1.331.461.81

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$3.68bn$3.50bn$3.47bn$3.80bn$3.94bn$4.01bn$3.67bn$4.35bn$1.34bn$1.22bn
Cash and short-term investments$310.9m$112.4m$93.7m$27.8m$247.8m$343.1m$152.3m$213.4m$74.2m$31.7m
Total liabilities$3.67bn$3.55bn$3.41bn$3.59bn$3.57bn$3.65bn$3.32bn$3.46bn$1.72bn$1.39bn
Debt$2.63bn$2.55bn$2.70bn$2.79bn$2.81bn$2.88bn$2.70bn$2.69bn$787.4m$831.3m
Shareholders' equity−$70.8m−$109.3m$19.8m$298.4m$360.3m$303.3m$232.0m$896.4m−$385.7m−$185.3m
Shares outstanding325m310m244m151m149m148m142m127m115m115m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$340.0m$295.1m$345.6m$65.1m$241.8m$379.0m$1.7m$250.2m$234.2m$115.1m
Capital spending−$70.1m−$75.0m−$69.2m−$90.6m−$47.7m−$61.8m−$97.4m−$97.1m−$114.3m−$124.6m
Free cash flow$269.9m$220.1m$276.4m−$25.5m$194.1m$317.2m−$95.7m$153.1m$119.9m−$9.5m
Dividends paid———−$3.6m———−$183.0m−$375.3m−$200.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$796.2m$722.5m$814.3m$784.5m$724.5m$695.4m$730.5m$702.5m
Operating income$126.0m$142.9m$111.5m$57.6m$116.8m$94.4m$75.8m$88.8m
Net income$57.7m$62.3m$35.1m$2.4m$22.4m$12.2m−$31.1m−$156,000
Diluted earnings per share0.180.190.110.010.070.04-0.10-0.00
Cash from operations−$19.0m−$28.0m$130.0m$118.0m$83.0m$7.0m$118.0m$141.0m
Capital spending−$45.0m−$13.0m−$43.0m−$15.0m−$26.0m−$18.0m−$23.0m−$20.0m
Free cash flow−$64.0m−$41.0m$87.0m$103.0m$57.0m−$11.0m$95.0m$121.0m
Total assets$3.78bn$3.54bn$3.68bn$3.60bn$3.42bn$3.37bn$3.50bn$3.46bn
Cash and short-term investments$127.6m$197.7m$310.9m$201.2m$81.2m$59.2m$112.4m$74.0m
Debt$2.69bn$2.59bn$2.59bn$2.59bn$2.48bn$2.49bn$2.50bn$2.55bn
Shareholders' equity$33.0m−$45.4m−$70.8m−$109.5m−$112.5m−$131.7m−$109.3m−$93.4m

Financial ratios

Data as of 20 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin12.6%7.3%11.3%9.0%8.0%5.5%
Net margin2.4%-4.2%-3.5%-5.9%0.5%4.6%
Return on equity-101.8%107.0%-424.6%-43.6%2.9%30.0%
Return on assets2.0%-3.3%-2.4%-3.4%0.3%2.3%
Free cash flow yield5.4%4.9%7.3%2.2%8.4%13.3%
Revenue growth8.0%16.7%8.2%5.7%5.1%22.5%
Earnings growth-161.6%39.2%-35.4%-1323.5%-88.3%-125.2%
Current ratio2.17x1.41x1.63x1.88x2.24x2.29x
Debt to equity-36.54x-22.90x134.22x9.04x7.57x9.21x
Equity ratio-1.9%-3.1%0.6%7.9%9.1%7.6%
Interest coverage1.58x0.79x1.29x1.26x1.23x0.75x
R&D as a share of sales6.2%6.8%8.1%9.4%10.0%9.6%
Buybacks as a share of market value-4.8%-27.1%-60.9%-1.4%-1.2%-4.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.9%8.7%13.3%
Operating income—35.9%6.4%
Net income—-4.6%-8.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin11.6%7.5%7.2%6.7%
Net margin-0.8%-2.5%-1.1%-0.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings56.8-21.0-17.6-2.367.37.4-1.9-6.5
Price to sales1.40.90.60.10.30.30.40.7

Market value over time

30 Nov 2016 to 19 Oct 2026, in USD

$1.03bn$6.35bn

Share price return

Finished calendar years

20252024202320222021202020192018
Return64%44%148%-53%5%-11%-47%-6%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.